The established role of the cGAS-STING pathway in promoting anti-tumor and anti-viral immunity has promoted the development of synthetic small molecule STING agonists that mimic the endogenous STING ligand cGAMP, several of which have entered clinical development (29, –, 32). This evidence concerns the gene STING1 and neoplasm.